Psychedelic Invest Podcast

On this episode of the Psychedelic Invest Podcast, host Bruce Eckfedlt is joined by Bjorn Hansen and Nathaniel Morris of Intiem. 

Bjorn Hansen is the CEO of Intiem. An accomplished entrepreneur with a background in both pharmaceuticals and electrical engineering, Bjorn is passionate about the potential for cannabis, psychedelics, and AI to transform the sexual wellness space.

Nathaniel Morris is the Chief Innovation Officer of Intiem. With more than 20 years of experience, Nathaniel is a cannabis and psychedelic SME profiled on PBS, MSNBC, and The Discovery Channel, and author of Transforming Orgasms with Psychedelics, Cannabis & Science.

On this episode of the Psychedelic Invest Podcast, host Bruce Eckfedlt is joined by Peter Grinspoon. 

Peter Grinspoon is a primary care doctor and medical cannabis specialist at Harvard Medical School for 25 years, as well as a certified Physician Coach for the MGH Physician Center for Well-being. He is an author ("Seeing Through the Smoke: A Cannabis Specialist Untangles the Truth About Marijuana", Prometheus). He is a medical and scientific consultant in the cannabis industries, with a focus on education.

He is also a Board Member of the Advocacy Group 'Doctors For Cannabis Legalization' which is working toward cannabis legalization and social justice. 

On this episode of the Psychedelic Invest Podcast, host Bruce Eckfeldt welcomes both Eric and David Rahn of Rahn & Associates.

Rahn & Associates offers business insurance coverage in highly-regulated industries like cannabis and psychedelics. Their latest division positioned for the psychedelics industry is called PSYINS.

Eric is a highly specialized insurance broker and risk management professional with over 30 years of experience providing tailor-made, hard-to-place insurance coverage to domestic and multinational public and private corporations, closely held family businesses, and high-net-worth individuals.

Eric stays ahead of the curve on industry trends, regulations, and resources to match his clients with premier insurance products that fit their precise needs and budget. He has built numerous long-lasting relationships with top global insurance partners, as well as legal, finance, and accounting professionals, to lead complex insurance deals that protect businesses from the biggest risks and challenges they face today.

A graduate of Babson College School of Entrepreneurial Studies, Eric held several executive positions in highly regulated industries, including maritime and casino/gaming, prior to starting his own firm, and leverages his extensive knowledge of corporate business practices to provide C-Suite Executives' critical risk management strategies that fully protect and safeguard themselves and their businesses

In this episode, Yuriy talks about his inspiration and why he feels so passionate about the intersection between technology and mental health.

David is a specialized insurance and risk management professional who assists companies operating in highly regulated industries to minimize their risks and access critical coverages to safeguard their businesses.

As a Bespoke Insurance Broker with strong analytical skills, he performs detailed risk assessments for both start-up and established public and private companies, and develops customized strategies and solutions to ensure their businesses and C-suite executives are fully protected.

Upon graduating from Lynn University, David launched his career in digital marketing and technology before transferring his skill sets to Rahn & Associates in 2016. Most recently, he was the Southeast Territory Manager for CannGen Insurance Services, a position that enabled him to bridge and strengthen the broker-carrier relationship.

David’s unique experience having worked on both the broker and carrier side of the business and his profound ability to understand a company’s risks and match it to the right coverages is a tremendous advantage for difficult-to-insure businesses operating in high-risk industries, such as Maritime, Cannabis and Psychedelic Medicine. He leverages his strong relationships with the world's leading insurance carriers and knowledge of all the various coverages available to companies, as well as what underwriting teams need, in order to secure the right coverages for his clients.

On this episode of the Psychedelic Invest Podcast, host Bruce Eckfeldt is joined by Yuriy Blokhin.

Yuriy is the Founder and CEO of Homecoming, which is a platform that gives coaches and therapists the tools to do their most impactful work.

In this episode, Yuriy talks about his inspiration and why he feels so passionate about the intersection between technology and mental health.

On this episode of the Psychedelic Invest Podcast, host Bruce Eckfeldt is joined by Jeremy Gardner.

Jeremy is the Founder and Managing Partner of Mystic Ventures.

In this episode, Jeremy talks about his interest in psychedelics, his history with cryptocurrencies, and how he sees the future playing out.

On this episode of the Psychedelic Invest Podcast, host Bruce Eckfeldt is joined by Olivia Mannix.

Olivia is an award-winning entrepreneur and cannabis & psychedelics business pioneer. Olivia is the intuitive leader of marketing and the business revolution. She founded one of the first ancillary cannabis companies, Cannabrand in 2013. Being the innovator behind the movement to destigmatize cannabis and psychedelics, she recognized these opportunities long before they were widely accepted. She has founded several other companies including a tech SaS platform and sales application. She founded the first female psychedelics biotech company for women’s health: Felicity Pharma, and is one of the only women-CEOs in this space. Olivia has been recognized by Forbes, PRWeek's Top 50 Innovators, Adweek's Young Influentials and is a contributor to Adweek and Rolling Stone.

On the season three premiere of the Psychedelic Invest Podcast, host Bruce Eckfeldt is joined by Joël Brierre.

Joel Brierre is the Founder and CEO of the psychedelic wellness companies Kaivalya Kollectiv and Tandava Retreats, as well as co-founder of the 5-MeO-DMT education and training platform, F.I.V.E.. Joel has been a leader in the modern psychedelic movement, specifically in the realm of 5-MeO-DMT and the Bufo Alvarius toad, and has spent years helping to create safe and effective protocols around this molecule. With a passion for preparation and integration protocols, Joel and his team are involved in everything from clinical research and trainings to experiential retreats in Mexico and Jamaica.

Logan Lenz is the CEO of Nucleus, a venture studio creating brands in the psychedelics industry. Nucleus is currently raising funds through crowdfunding on Wefunder, and allowing anyone to invest in their portfolio of twelve brands with as little as $200. 

As a much-needed disclaimer, Nucleus owns and operates Psychedelic Invest.

On this episode of the Psychedelic Invest Podcast, we welcome Tim Schlidt of Palo Santo.

Palo Santo is a leading therapeutics investment fund dedicated to increasing the global supply of clinically effective and accessible healthcare solutions.

Tim is a Co-Founder and Partner of the fund, sits on the Board of many psychedelics companies, and recently closed a $50 million fund.

Tune in to learn more about Palo Santo's investment thesis, portfolio, and goals for the future of psychedelic-assisted therapies and beyond.

On this episode of the Psychedelic Invest Podcast, we welcome Anand Shahi of BAR Capital.

BAR Capital is a family office focused on continuously raising the standards of excellence for the stewardship of wealth.

Tune in to learn more about how the cannabis industry relates to psychedelics and how trends and patterns might allow us to predict future outcomes. As an investor himself, Anand shines a light on how these comparisons can lead to investment opportunities now and down the road.

On this episode of the Psychedelic Invest Podcast, Bruce Eckfeldt is joined by two of the co-founders of Anuma, a digital group therapeutics startup. Anuma is creating unique VR experiences for palliative care and beyond. 

Tune in to learn more about the men behind this novel idea, what the company is focusing on now, and how their work is positioned relative to the psychedelics industry as a whole.

On this episode of the Psychedelic Invest Podcast, we welcome Jordan Tishler.

Jordan is a lot of things. All of those things revolve around him being a very hard-working and intelligent doctor and entrepreneur.

For starters, he is the CEO of InhaleMD. He's also a Professor at Harvard and the President of the Association of Cannabinoid Specialists.

We're quite fortunate he was able to sit down with host, Bruce Eckfeldt to record this amazing conversation.

We hope you enjoy.

Robbie Bent joins host Bruce Eckfeldt for a conversation about the future of well-being.

More specifically, Robbie is building a platform that includes physical spaces, a mobile app, a concert tour, and a global community.

His company is called Othership and his commitment to helping as many people as possible is clear and obvious.

We hope you enjoy this conversation.

Itzhak Beery joins the Psychedelic Invest Podcast for episode #17. 

Itzhak considers himself a "modern-day shaman." In this episode, we learn what it means to bring old traditions into modern times. 

On this episode of the Psychedelic Invest Podcast, we welcome Doug Finkelstein.

Doug is the Chief Empathy Officer of Empathic Health, a community membership program connecting individuals with events and each other.

During the conversation, Doug highlights his history with plant medicines and how and why Empathic Health was formed. 

Season two episode two brings us a delightful conversation between host Bruce Eckfeldt and Amanda Reiman.

Amanda Reiman, among many other things, is the Co-Founder of Secret Garden, the VP of Public Policy Research at New Frontier Data, and Founder of Personal Plants.

Amanda calls herself a social ethnobotanist. She has been studying the relationship between people and plant medicines for over 20 years. She was one of the first people to explore the use of cannabis as a substitute for alcohol and other drugs. She founded Personal Plants in 2020 to create space for everyone to grow and process their own medicinal plants.

We hope you enjoy the conversation.

To kick things off for season two, host Bruce Eckfeldt is joined by the Co-Founder and CEO of Beckley Retreats, Neil Markey.

As a Captain in the US Army Special Operations 2nd Ranger Battalion, Neil was deployed once to Iraq, and twice to Afghanistan. After, as an MBA/MIA master's student at Columbia University, he suffered from depression and PTSD. This led him to alternative well-being practices and marked the start of a profound healing journey with mindfulness and psychedelics. Prior to Beckley Retreats, Neil worked as the Chief Growth Officer for a $450M private equity portfolio company where he was responsible for all strategy and growth planning. Before that he worked as a consultant at McKinsey & Co, where he co-led the internal mindfulness program.

Dustin Robinson of Iter Investments joins host Bruce Eckfeldt for a special edition of the Psychedelic Invest Podcast. In this edition of Psychedelic Investors, the pair talk about the momentum being built in the psychedelics industry and what the future holds for the adoption of psychedelic medicines and treatments.

Jordan Youkilis of Key Investment Partners joins host Bruce Eckfeldt for a special edition of the Psychedelic Invest Podcast. In this edition of Psychedelic Investors, the pair talk about cannabis, psychedelics, and how the future is shaping up for business and the world at large. 

In the first episode of the special edition of the Psychedelic Invest Podcast, host Bruce Eckfeldt talks with Cody Shandraw, the Managing Partner at Ambria Capital and Phyto Partners, about the current wave of psychedelic companies and investments. 

Cody has made significant investments in a wide range of psychedelics companies. All the while, he and his funds have maintained their bullish outlook on the impact that mission-driven entrepreneurs can have on humanity.